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Comparison of Chromogenic Media for Recovery of Carbapenemase-
Producing Enterobacteriaceae (CPE) and Evaluation of CPE Prevalence
at a Tertiary Care Academic Medical Center
Morgan A. Pence,a Tiffany Hink,b Carey-Ann D. Burnhama
Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine,a and Department of Medicine, Division of Infectious Diseases,b Washington
University School of Medicine, St. Louis, Missouri, USA
We evaluated the performance characteristics of chromID CARBA and HardyCHROMCarbapenemase for the detection of car-
bapenemase-producing Enterobacteriaceae (CPE). A CPE prevalence study was conducted using chromID CARBA; this demon-
strated that in low-prevalence settings, CPE screening agars may lack specificity, and confirmation of putative isolates is
necessary.
Over the last decade, carbapenem-resistant Enterobacteriaceae(CRE) have disseminated worldwide (1–4). Carbapenem re-
sistance can be mediated by multiple mechanisms, including en-
zymes that can inactivate carbapenems (carbapenemases) or the
presence of efflux or porin mutations. Perhaps the most alarming
are the carbapenemase-producing isolates, which are frequently
housed on mobile genetic elements, are resistant to most (if not
all) -lactams, and are often resistant to multiple other classes of
drugs as well.
Due to the lack of therapeutic options for these organisms,
tremendous efforts have been focused on preventing the spread of
carbapenemase-producing Enterobacteriaceae (CPE). In order to
identify and isolate asymptomatic carriers, active surveillance for
fecal carriage in hospitalized patients is becoming increasingly
common.
The objective of this study was to compare the limit of detection
(LOD) of two commercially available chromogenic agars, chromID
CARBA (bioMérieux, Durham, NC) and HardyCHROM Carbapen-
emase (recently renamed HardyCHROM CRE; Hardy Diagnostics,
Santa Maria, CA), for the recovery of CPE from clinical specimens. In
addition, a prevalence study was conducted to determine the rate of
fecal and respiratory carriage of CPE at Barnes-Jewish Hospital (St.
Louis, MO), a tertiary care academic medical center.
(This work was presented in part at the 114th General Meeting
of the American Society for Microbiology, Boston, MA, 17 to 20
May 2014.)
For the LOD analysis, CPE-negative remnant stool specimens
from Clostridium difficile testing were pooled, divided into 5-ml
aliquots, and frozen at20°C until use. Bacteria were inoculated
into stool specimens, resulting in a series of specimens with a final
concentration of 101 to 104 CFU/ml. To mimic a rectal swab spec-
imen, an ESwab (Copan Diagnostics, Murrieta, CA) was placed
into the stool and subsequently into ESwab transport media. After
1 h at room temperature, the swab was vortexed, and 1 drop of the
specimen was inoculated onto chromID CARBA and Hardy-
CHROM Carbapenemase agars. After 24 h, the plates were evalu-
ated, and LOD was determined for each isolate (n 12) (Table 1).
A total of three replicates were performed.
For comparison, 1 drop of the ESwab specimen was also added
to 5 ml of tryptic soy broth (TSB) containing a 10-g meropenem
disk (BD Diagnostics, Franklin Lakes, NJ; CDC method) (5). The
next day, 1 drop of the TSB was inoculated onto chromID CARBA
and HardyCHROM Carbapenemase agars. After 24 h, the plates
were examined, and the LOD was determined for each isolate.
Two replicates were performed. A third replicate was performed
using a larger volume, 100 l of TSB, which was inoculated onto
both chromogenic agars.
The Barnes-Jewish Hospital prevalence study was carried out
over 12 weeks, from October 2013 to January 2014. This study was
approved by the Washington University School of Medicine Hu-
man Research Protection Office. Remnant stool and rectal swab
specimens submitted for C. difficile testing, C. difficile testing plus
enteric culture, or vancomycin-resistant enterococci (VRE) screen-
ing, as well as tracheal aspirate specimens, were deidentified by an
honest broker. A 10-l loop of specimen was inoculated onto
chromID CARBA agar, with the exception of VRE swabs, which
were inoculated directly onto the agar. Multiple lot numbers of
chromID CARBA were used. The plates were examined for
growth after 24 and 48 h of incubation. All growth was subcul-
tured to blood agar plates (BD Diagnostics) and incubated over-
night. The next day, isolates were Gram stained and subsequently
analyzed by matrix-assisted laser desorption ionization–time of
flight mass spectrometry (MALDI-TOF MS) on the Vitek MS
(IVD v.2.0; bioMérieux) (6–9). If identification was not achieved,
the isolates were analyzed by the Bruker Biotyper (library version
3.4; Bruker Daltonics, Billerica, MA) (10, 11).
A subset of 60 specimens from the prevalence study, submitted
for C. difficile testing, were inoculated onto both chromID CARBA
Received 9 November 2014 Accepted 12 November 2014
Accepted manuscript posted online 19 November 2014
Citation Pence MA, Hink T, Burnham C-AD. 2015. Comparison of chromogenic
media for recovery of carbapenemase-producing Enterobacteriaceae (CPE) and
evaluation of CPE prevalence at a tertiary care academic medical center. J Clin
Microbiol 53:663–666. doi:10.1128/JCM.03208-14.
Editor: G. V. Doern
Address correspondence to Carey-Ann D. Burnham, cburnham@path.wustl.edu.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.03208-14
February 2015 Volume 53 Number 2 jcm.asm.org 663Journal of Clinical Microbiology
and HardyCHROM Carbapenemase media, as described above,
for direct comparison of the two media.
Antimicrobial susceptibility testing was performed on all
Gram-negative organisms recovered on chromID CARBA agar
using Kirby-Bauer disk diffusion. Categorical interpretation of
zone sizes for all antimicrobials was based on the 2013 Clinical and
Laboratory Standards Institute (CLSI) disk diffusion criteria (12).
Although carbapenem disk diffusion breakpoints do not exist for
nonfermenting Gram-negative bacilli, disk diffusion was used as
an initial screen for carbapenem resistance. All Enterobacteriaceae
and Pseudomonas putida isolates and carbapenem-nonsusceptible
Pseudomonas aeruginosa isolates were tested for the blaKPC (13),
blaNDM-1 (14), blaIMP, and blaVIM (15) genes by real-time PCR
on the Cepheid SmartCycler II (Cepheid, Sunnyvale, CA). In ad-
dition, all carbapenem-nonsusceptible Enterobacteriaceae were
tested for the presence of the blaCTX-M gene using conventional
PCR detected by agarose gel electrophoresis (15).
Six (50%) of the 12 isolates did not grow at the highest concen-
tration tested (104 CFU/ml) on HardyCHROM carbapenemase
agar, including Klebsiella pneumoniae carbapenemase (KPC)-pro-
ducing strains of Escherichia coli and Citrobacter freundii complex,
whereas a single isolate did not grow on the chromID CARBA agar
(a Providencia rettgeri NDM-1–producing isolate). For the isolates
that did grow, the limit of detection was determined to be 102 to
104 CFU/ml (Table 1).
Based on our initial findings demonstrating a superior LOD,
chromID CARBA was selected for the prospective prevalence
study. A total of 611 specimens, including 561 fecal samples and 50
tracheal aspirates, were inoculated directly onto chromID CARBA
agar. Of the 561 fecal specimens, 450 were submitted for C. difficile
toxin testing and 111 were submitted for VRE screening. Forty-
nine of the isolates submitted for C. difficile testing were also sub-
mitted for enteric culture. The specimens represented multiple
patient age groups and hospital units, including intensive care and
oncology.
Of the 611 specimens inoculated onto chromID CARBA, 139
isolates were recovered from 131 specimens. The breakdown of
organisms recovered is shown in Table 2. Of the 9 Enterobacteria-
ceae isolates, 6 were recovered after 24 h of incubation, and 3
isolates were recovered after 48 h of incubation. After 24 h, the
overall specificity was 70%, and the specificity was 95.3% based
upon interpretation of the chromogenic medium.
A subset of 60 specimens from the point prevalence study were
inoculated onto both chromID CARBA and HardyCHROM Car-
bapenemase to directly compare the performance of the two
media using clinical specimens. After 24 h, 2 isolates, P. aerugi-
nosa and Pseudomonas sp., were recovered on chromID CARBA
(96.7% overall specificity; 100% specificity based upon direct
interpretation of the chromogenic medium). From the same
60 specimens, 12 Enterococcus spp. were recovered on Hardy-
CHROM carbapenemase (80% overall specificity; 100% specific-
ity based upon direct interpretation of the chromogenic medium).
After 48 h of incubation, 10 additional isolates were recovered on
TABLE 1 Limits of detection for chromID CARBA and HardyCHROM carbapenemase media using spiked stool specimensa
Strain
Limit of detection (CFU/ml) with direct inoculation
Limit of detection (CFU/ml) with CDC
method
ChromID CARBA HardyCHROM Carbapenemase ChromID CARBA HardyCHROM
KPC isolates
Klebsiella pneumoniae BAA-1705 103 104 Not recovered Not recovered
Klebsiella pneumoniae 102 103 Not recovered Not recovered
Escherichia coli 1 103 Not recovered Not recovered Not recovered
Escherichia coli 2 103 103 104 104
Enterobacter cloacae complex 1 103 Not recovered Not recovered Not recovered
Enterobacter cloacae complex 2 102 Not recovered Not recovered Not recovered
Citrobacter freundii complex 1 103 Not recovered Not recovered Not recovered
Citrobacter freundii complex 2 102 Not recovered Not recovered Not recovered
NDM-1 isolates
Klebsiella pneumoniae BAA-2146 102 102 102 102
Escherichia coli 103 103 Not recovered Not recovered
Enterobacter cloacae complex 102 103 Not recovered Not recovered
Providencia rettgeri Not recovered Not recovered Not recovered Not recovered
a Tested serial dilutions, 101 to 104 CFU/ml.










isolatesa24 h 48 h
Aeromonas sp. 1 0 1 NA
Burkholderia multivorans 0 1 1 NA
Candida sp. 1 35 36 NA
Citrobacter freundii complex 1 1 2 0/2
Enterobacter sp. 2 1 3 0/3
Escherichia coli 1 0 1 0/1
Enterococcus sp. 1 22 23 NA
Klebsiella oxytoca 1 1 2 1/2
Pseudomonas aeruginosa 27 23 50 0/10
Pseudomonas sp. 3 6 9 0/3
Stenotrophomonas maltophilia 4 6 10 NA
Serratia marcescens 1 0 1 0/1
Total 43 96 139 1/22
a Isolates were tested for the presence of blaKPC, blaNDM-1, blaIMP, and blaVIM. NA, PCR
not performed.
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chromID CARBA, decreasing the overall specificity to 80%. An
additional 18 isolates were recovered on HardyCHROM Carbap-
enemase after 48 h of incubation, resulting in an overall specificity
of 50%.
Three of the 9 Enterobacteriaceae isolates recovered on chromID
were susceptible to all carbapenems tested (Table 3). In addition,
40 of 50 P. aeruginosa isolates recovered were susceptible to imi-
penem and meropenem, while 10 isolates were nonsusceptible to
both of these carbapenems.
Eight Enterobacteriaceae (n 9), all P. putida (n 3), and all
carbapenem-nonsusceptible P. aeruginosa (n  10) isolates were
negative according to PCR for the blaKPC (13), blaNDM-1 (14),
blaIMP, and blaVIM genes (15). One isolate of Klebsiella oxytoca was
positive for the blaKPC gene. However, this isolate was susceptible
to all four carbapenems as tested by disk diffusion. Additionally,
the K. oxytoca isolate and the E. coli isolate were positive for the
blaCTX-M gene (15).
Our findings contrast with those of Papadimitriou-Olivgeris et
al. (16), who recently published a report evaluating chromID
CARBA for detection of CPE from rectal swabs at a hospital in
Greece. Their study evaluated fewer specimens (n  177) and
included only patients in intensive care, and the recovery of CPE
was significantly higher (89 CPE from 86 specimens). A single
isolate of Enterobacter cloacae was the only Enterobacteriaceae iso-
late recovered on chromID CARBA that did not produce a car-
bapenemase. The sensitivity of chromID CARBA at the patient
level was 96.5%, while the specificity was 91.2% based upon the
direct interpretation of the chromogenic medium and increased
to 100% when Gram stain characteristics were included in the
interpretation algorithm.
Day and colleagues (17, 18) recently published two articles
investigating the prevalence of CPE in Pakistan using chromo-
genic media. Both studies had fewer subjects than our study (n
175 and 152) and had higher rates of CPE (18.3% and 8.6%). The
reported sensitivities of the chromogenic media were 100% and
92% in these studies, and both studies demonstrated recovery of
non-CPE Enterobacteriaceae and significant numbers of Pseu-
domonas spp. While the analytical performance characteristics of
chromID CARBA are favorable in areas of high prevalence (16–
18), the positive predictive value of this medium for screening
decreases in low-prevalence settings.
Both chromID CARBA and HardyCHROM carbapenemase
are subject to breakthrough with non-CPE organisms. The colony
morphology of non-Enterobacteriaceae isolates was distinct from
that of Enterobacteriaceae, with the exception of the Aeromonas
isolate, which was burgundy and resembled E. coli. In addition to
the breakthrough of non-Enterobacteriaceae, chromID CARBA is
also subject to growth of non-CPE Enterobacteriaceae. As a result
of the proportion of non-CPE isolated on this medium, we rec-
ommend that all Enterobacteriaceae be confirmed as carbapen-
emase producing before reporting the presence of a CPE in the
specimen. This can add to the turnaround time of the testing.
Although Enterobacteriaceae isolates were morphologically dis-
tinct from other species recovered on the agar, there were no mor-
phological differences between CPE and non-CPE isolates to
guide this analysis prior to the subsequent characterization of the
isolates.
Overall, chromID CARBA has analytical performance charac-
teristics for CPE superior to those of HardyCHROM Carbapen-
emase agar. During initial testing, LODs for chromID CARBA
were typically a log or more sensitive than those observed for the
HardyCHROM Carbapenemase medium. While it is unclear if
this difference is clinically significant, due to a paucity of data on
the typical fecal burden of CPE, it is not uncommon for laborato-
ries to select a screening approach with the best analytical sensi-
tivity. Based on our low prevalence, it is unlikely that routine
screening for CPE would be justified or cost-effective at our hos-
pital. Health care institutions may want to conduct prevalence
studies to gain a snapshot of local or institutional CPE carriage
and inform the need for screening and preventive measures to
control the spread of these important pathogens in their institu-
tion.
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